Skip to main content
    A

    Anebulo Pharmaceuticals Inc (ANEB)

    Official site

    BIOTECHNOLOGY

    $0.28
    +0.28 (+11100.00%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Anebulo Pharmaceuticals Inc (ANEB) Financials: Revenue, Profit and Cash Flow

    Updated Feb 12, 2026. Financial statements from company filings, amounts in US dollars.

    Anebulo Pharmaceuticals reported revenue of $0 for the fiscal year ended Jun 30, 2025. That year, net income was -$8.48M, operating cash flow was -$6.35M and free cash flow was -$6.35M. The quarter ended Dec 31, 2025 had revenue of $0 and net income of -$2.00M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Jun 2025, with an operating loss of $9.22M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2025$0N/AN/AN/AN/A
    Jun 2024$0N/AN/AN/AN/A
    Jun 2023$0N/AN/AN/AN/A
    Jun 2022$0N/AN/AN/AN/A
    Jun 2021$0N/AN/AN/AN/A
    Jun 2020N/AN/AN/AN/AN/A
    Annual, fiscal years ended Jun 2020 to Jun 2025

    Income Statement

    In the fiscal year ended Jun 2025, the net loss widened from the year before. In the quarter ended Dec 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemJun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
    Research and development$4.30M$3.55M$5.60M$2.96M$2.27M$150.00K
    Operating income-$9.22M-$8.31M-$11.78M-$6.83M-$3.61M-$173.35K
    Net income-$8.48M-$8.20M-$11.73M-$6.83M-$30.25M-$174.64K
    EBITDA-$7.98M-$8.15MN/AN/AN/A-$173.35K
    Fiscal years ended Jun 2020 to Jun 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating income-$2.62M-$2.26M-$2.33M-$1.89M-$2.59M-$2.41M-$1.34M-$1.66M-$2.76M-$2.54M-$2.49M-$2.86M
    Net income-$2.00M-$2.16M-$2.14M-$1.68M-$2.46M-$2.20M-$1.35M-$1.65M-$2.72M-$2.48M-$2.50M-$2.80M
    Last 12 quarters

    Balance Sheet

    As of Jun 2025, cash and equivalents of $11.63M were 95.7% of total assets of $12.15M, against total liabilities of $487.69K.

    Annual

    Line itemJun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019
    Total assets$12.15M$4.07M$11.67M$15.58M$21.65M$3.03M$3.03M
    Current assets$11.96M$3.51M$11.67M$15.58M$21.65M$3.03M$3.03M
    Cash and equivalents$11.63M$3.09M$11.25M$14.55M$19.99M$3.02M$3.02M
    Total liabilities$487.69K$260.58K$1.07M$512.53K$241.63K$223.87K$223.87K
    Short-term debtN/AN/AN/AN/AN/A$201.29K$201.29K
    Shareholder equity$11.66M$3.81M$10.60M$15.07M$21.41M-$171.14K-$171.14K
    Fiscal years ended Jun 2019 to Jun 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets$9.42M$10.70M$12.15M$14.01M$15.84M$2.47M$4.07M$6.00M$7.50M$9.05M$11.67M$14.43M
    Total liabilities$1.49M$963.82K$487.69K$546.03K$878.80K$569.23K$260.58K$1.01M$1.01M$716.56K$1.07M$1.49M
    Cash and equivalents$9.04M$10.35M$11.63M$13.28M$15.00M$1.40M$3.09M$5.15M$6.64M$8.52M$11.25M$14.16M
    Shareholder equity$7.94M$9.74M$11.66M$13.46M$14.96M$1.90M$3.81M$4.99M$6.49M$8.33M$10.60M$12.94M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2025.

    Annual

    Line itemJun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
    Operating cash flow-$6.35M-$8.09M-$9.68M-$5.44M-$4.87M-$150.77K
    Capital expenditures$3$1$0$4$0$2
    Free cash flow-$6.35M-$8.09M-$9.68M-$5.44M-$4.87M-$150.77K
    Dividends paidN/AN/AN/AN/A$8.21MN/A
    Share repurchasesN/AN/A$317.08K$0N/AN/A
    Financing cash flow$14.88M-$62.35K$6.38M$0$21.83M$3.18M
    Fiscal years ended Jun 2020 to Jun 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-$1.31M-$1.27M-$1.65M-$1.60M-$1.41M-$1.69M-$2.05M-$1.50M-$1.81M-$2.73M-$2.85M-$2.19M
    Capital expenditures$0$0$0$0$4$0$1$0$3$5$4$0
    Free cash flow-$1.31M-$1.27M-$1.65M-$1.60M-$1.41M-$1.69M-$2.05M-$1.50M-$1.81M-$2.73M-$2.85M-$2.19M
    Last 12 quarters

    Frequently Asked Questions About ANEB

    What is Anebulo Pharmaceuticals' annual revenue?

    Anebulo Pharmaceuticals reported revenue of $0 for the fiscal year ended Jun 30, 2025.

    Is Anebulo Pharmaceuticals profitable?

    No. Anebulo Pharmaceuticals reported net income of -$8.48M for the fiscal year ended Jun 30, 2025.

    How much free cash flow does ANEB generate?

    For the fiscal year ended Jun 30, 2025, operating cash flow of -$6.35M minus capital expenditures of $3 produced free cash flow of -$6.35M.

    How much debt does Anebulo Pharmaceuticals have?

    The balance sheet dated Jun 30, 2025 reported cash and equivalents of $11.63M.